Other News To Note

•Anavex Life Sciences Corp., of New York, said a report has been published in Neuropsychopharmacology demonstrating that Anavex 2-73 dose-dependently blocks Tau and amyloid-beta proteins and memory deficit in a mouse model of Alzheimer’s disease (AD).